Search research articles
Contact Us
Filters
Showing results (1-10 of 99) with videos related to
Page
of 10
Sort By:
Leukemia & Lymphoma
|
February 24, 2009
Will changing the face of WT1 make it more attractive to T cells?
Justin Kline
Haematologica
|
March 16, 2023
The lymphoma microenvironment comes of age in the R-CHOP era?
Alan Cooper, Justin Kline
Journal for Immunotherapy of Cancer
|
December 20, 2013
Immune evasion in acute myeloid leukemia: current concepts and future directions
Ryan M Teague, Justin Kline
Expert Opinion on Pharmacotherapy
|
August 24, 2006
Nelarabine in the treatment of refractory T-cell malignant diseases
Justin Kline, Richard A Larson
Journal for Immunotherapy of Cancer
|
July 23, 2015
Update on checkpoint blockade therapy for lymphoma
Justin Kline, Michael R Bishop
Current Opinion in Investigational Drugs (London, England : 2000)
|
December 15, 2010
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer
Justin Kline, Thomas F Gajewski
Advances in Immunology
|
November 23, 2023
MHC cross-dressing in antigen presentation
Brendan W MacNabb, Justin Kline
Frontiers in Oncology
|
April 28, 2015
Targeting the innate immune system as immunotherapy for acute myeloid leukemia
Emily Curran, Leticia Corrales, Justin Kline
Blood
|
May 7, 2009
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
Long Zhang, Thomas F Gajewski, Justin Kline
Cell Research
|
April 27, 2016
MYC - a thorn in the side of cancer immunity
Stefani Spranger, Thomas F Gajewski, Justin Kline
Page
of 10
Search research articles
Search
Showing results (1-10 of 99) with videos related to
Sort By:
Page
of 10
Leukemia & Lymphoma
|
February 24, 2009
Will changing the face of WT1 make it more attractive to T cells?
Justin Kline
Haematologica
|
March 16, 2023
The lymphoma microenvironment comes of age in the R-CHOP era?
Alan Cooper, Justin Kline
Journal for Immunotherapy of Cancer
|
December 20, 2013
Immune evasion in acute myeloid leukemia: current concepts and future directions
Ryan M Teague, Justin Kline
Expert Opinion on Pharmacotherapy
|
August 24, 2006
Nelarabine in the treatment of refractory T-cell malignant diseases
Justin Kline, Richard A Larson
Journal for Immunotherapy of Cancer
|
July 23, 2015
Update on checkpoint blockade therapy for lymphoma
Justin Kline, Michael R Bishop
Current Opinion in Investigational Drugs (London, England : 2000)
|
December 15, 2010
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer
Justin Kline, Thomas F Gajewski
Advances in Immunology
|
November 23, 2023
MHC cross-dressing in antigen presentation
Brendan W MacNabb, Justin Kline
Frontiers in Oncology
|
April 28, 2015
Targeting the innate immune system as immunotherapy for acute myeloid leukemia
Emily Curran, Leticia Corrales, Justin Kline
Blood
|
May 7, 2009
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
Long Zhang, Thomas F Gajewski, Justin Kline
Cell Research
|
April 27, 2016
MYC - a thorn in the side of cancer immunity
Stefani Spranger, Thomas F Gajewski, Justin Kline
Page
of 10